Basic Stats
| LEI | 5493003G4YVJPVDW6U67 |
| CIK | 811641 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ImmuCell Corporation
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 20, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 25, 2025 |
ALLONGE TO AND AMENDMENT OF LINE OF CREDIT LOAN NO. 8160005222 Exhibit 10.1 ALLONGE TO AND AMENDMENT OF LINE OF CREDIT LOAN NO. 8160005222 AGREEMENT made this 20 day of August 2025, between Immucell Corporation a Maine corporation (hereinafter called “Borrower”) and MAINE COMMUNITY BANK, successor by merger to GORHAM SAVINGS BANK, a Maine banking corporation with principal place of business at 10 Wentworth Drive, Gorham, Maine 04038 (the “Bank”). Reference is |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identifica |
|
| August 14, 2025 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025 For Immediate Release PORTLAND, Maine – August 14, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 12, 2025 |
ImmuCell Announces Bank Debt Refinancing Exhibit 99.1 ImmuCell ImmuCell Announces Bank Debt Refinancing For Immediate Release PORTLAND, Maine – August 12, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced it has succe |
|
| August 12, 2025 |
Promissory Note executed by the Company in favor of Maine Community Bank dated as of August 7, 2025. Exhibit 10.2 PROMISSORY NOTE (Term Promissory Note) Up to $2,327,119.00 August 7, 2025 Portland, Maine FOR VALUE RECEIVED, IMMUCELL CORPORATION., a Delaware business corporation doing business in Maine, having a mailing address of 56 Evergreen Drive, Portland, Maine 04103(“Borrower”), hereby promises to pay to the order of Maine Community Bank, a Maine financial institution having a mailing addres |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 07, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 12, 2025 |
Loan Agreement between the Company and Maine Community Bank dated as of August 7, 2025. Exhibit 10.1 LOAN AGREEMENT by and among IMMUCELL CORPORATION, as Borrower, - and - Maine Community Bank, as Lender August 7, 2025 LOAN AGREEMENT THIS LOAN AGREEMENT (as the same may be amended, restated, replaced, supplemented, or otherwise modified and in effect from time to time, this “Agreement”) is made as of this 7th day of August, 2025, by and among IMMUCELL CORPORATION, a Delaware business |
|
| July 9, 2025 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 For Immediate Release PORTLAND, Maine – July 9, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, t |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 9, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 25, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 25, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 25, 2025 |
ImmuCell Embarks on CEO Succession Planning Process Exhibit 99.1 ImmuCell ImmuCell Embarks on CEO Succession Planning Process For Immediate Release PORTLAND, Maine – June 25, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced tha |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identific |
|
| May 14, 2025 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025 For Immediate Release PORTLAND, Maine – May 14, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and b |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☒ Defini |
|
| April 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 08, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 8, 2025 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 For Immediate Release PORTLAND, Maine – April 8, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, |
|
| April 7, 2025 |
ImmuCell Hires Chief Financial Officer Exhibit 99.1 ImmuCell ImmuCell Hires Chief Financial Officer For Immediate Release PORTLAND, Maine – April 7, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hire |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 4, 2025 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 7, 2025 |
Incentive Compensation Agreement between the Company and Timothy C. Fiori dated as of April 4, 2025 Exhibit 10.1 INCENTIVE COMPENSATION AGREEMENT This Incentive Compensation Agreement, dated as of April 4, 2025, is by and between IMMUCELL CORPORATION, a Delaware corporation (the “Company”) and TIM FIORI (the “Executive”). WHEREAS, the Executive has agreed to serve as the Company’s Chief Financial Officer; and WHEREAS, the Company wishes to provide the Executive with certain incentive compensatio |
|
| March 28, 2025 |
Insider Trading Policy of the Company adopted as of December 11, 2024. Exhibit 19 ImmuCell Corporation INSIDER TRADING POLICY Purpose This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the common stock of ImmuCell Corporation (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of incorporation) (I.R.S. Employer Identification N |
|
| March 28, 2025 |
Exhibit 10.11 AMENDED AND RESTATED INCENTIVE COMPENSATION AND SEVERANCE AGREEMENT This Amended and Restated Incentive Compensation and Severance Agreement, dated as of March 27, 2025, is by and between IMMUCELL CORPORATION, a Delaware corporation (the “Company”) and BOBBI JO BROCKMANN (the “Executive”), and replaces and supersedes in its entirety the Fourth Amended and Restated Incentive Compensat |
|
| March 28, 2025 |
Exhibit 10.10 INCENTIVE COMPENSATION AGREEMENT This Incentive Compensation Agreement, dated as of March 27, 2025, is by and between IMMUCELL CORPORATION, a Delaware corporation (the “Company”) and MICHAEL F. BRIGHAM (the “Executive”). WHEREAS, the Executive serves as the Company’s President, Chief Executive Officer, Treasurer and Secretary; and WHEREAS, the Company wishes to provide the Executive |
|
| February 25, 2025 |
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024 For Immediate Release PORTLAND, Maine – February 25, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivi |
|
| February 25, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 16, 2025 |
Exhibit 99.1 ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses For Immediate Release PORTLAND, Maine – January 16, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and pro |
|
| January 10, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2025 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 10, 2025 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024 For Immediate Release PORTLAND, Maine – January 9, 2025 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and |
|
| December 9, 2024 |
Exhibit 10.1 December 6, 2024 Via Hand Delivery Elizabeth L. Williams 92 Kindred Way Yarmouth, Maine 04096 RE: Employment and Separation Agreement Dear Betsy: As we discussed, your employment at ImmuCell Corporation (the “Company”) will change from full time to part time effective December 7, 2024, and you have elected to voluntarily retire effective July 1, 2025 (the “Separation Date”). You are a |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 6, 2024 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 2, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 29, 2024 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 2, 2024 |
Exhibit 10.1 AMENDING AGREEMENT THIS AMENDING AGREEMENT is dated November 29, 2024 PARTIES: 1. NORBROOK LABORATORIES LIMITED, a company incorporated and registered in Northern Ireland with company number NI007665 and whose registered office address is at Station Works, Camlough Road, Newry, Co Down, BT35 6JP, Northern Ireland (“NORBROOK”); and 2. IMMUCELL CORPORATION a corporation duly organised a |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Ident |
|
| November 13, 2024 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024 For Immediate Release PORTLAND, Maine – November 13, 2024 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of da |
|
| November 13, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 8, 2024 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024 For Immediate Release PORTLAND, Maine – October 8, 2024 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, t |
|
| October 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 8, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 20, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 24, 2024 |
Amended and Restated By-Laws of ImmuCell Corporation, amended through September 20, 2024. Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF IMMUCELL CORPORATION A DELAWARE CORPORATION AS AMENDED THROUGH SEPTEMBER 20, 2024 Table of Contents ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1. Place of Meetings 1 Section 2. Annual Meeting 1 Section 3. Special Meetings 1 Section 4. Notice of Meetings 1 Section 5. Voting List 1 Section 6. Quorum 2 Section 7. Adjournments 2 Section 8. Action at Meetin |
|
| September 24, 2024 |
Exhibit 10.1 FIFTH AMENDMENT OF LEASE This is a Fifth Amendment of Lease (this “Amendment”) dated as of this 20th day of September 2024, by and between TVP, LLC, with a mailing address of P.O. Box 66749, Falmouth, Maine 04105 (hereinafter the “Landlord”), and ImmuCell Corporation with a mailing address of 56 Evergreen Drive, Portland, Maine 04103 (hereinafter the “Tenant”). WHEREAS, the parties en |
|
| August 27, 2024 |
ICCC / ImmuCell Corporation / Knudsen Ejnar A III - SC 13D Activist Investment SC 13D 1 d858394dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ImmuCell Corporation (Name of Issuer) Common Stock, par value $.10 per share (Title of Class of Securities) 45252306 (CUSIP Number) Ejnar A. Knudsen III 212 West Superior, Suite 500 Chicago, IL 60654 (530) 564-0626 (Name, |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identifica |
|
| August 13, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 13, 2024 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024 For Immediate Release PORTLAND, Maine – August 13, 2024 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and |
|
| July 9, 2024 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024 For Immediate Release PORTLAND, Maine – July 9, 2024 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, toda |
|
| July 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 9, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 11, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 14, 2024 |
Exhibit 10.1 FOURTH AMENDMENT OF LEASE This is a Fourth Amendment of Lease (this “Amendment”) dated as of this 11th day of June 2024, by and between TVP, LLC, with a mailing address of P.O. Box 66749, Falmouth, Maine 04105 (hereinafter the “Landlord”), and ImmuCell Corporation with a mailing address of 56 Evergreen Drive, Portland, Maine 04103 (hereinafter the “Tenant”). WHEREAS, the parties enter |
|
| June 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 13, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 6, 2024 |
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® Exhibit 99.1 ImmuCell ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® For Immediate Release PORTLAND, Maine – June 5, 2024 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of da |
|
| May 22, 2024 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D and all amendments thereto with respect to the common stock of ImmuCell Corporation, and that this Joint Filing Agreement (this “Agreement”) be included as an Exhibit |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identific |
|
| May 14, 2024 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024 For Immediate Release PORTLAND, Maine – May 14, 2024 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and b |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☒ Defini |
|
| April 10, 2024 |
IMMUCELL CORPORATION Common Stock Filed Pursuant to Rule 424(b)(2) File No. 333-278438 Prospectus IMMUCELL CORPORATION $11,000,000 Common Stock We have entered into an At The Market Offering Agreement, or the sales agreement, with Craig-Hallum Capital Group LLC (“Craig-Hallum” or the “Agent”) acting as sales agent, on April 9, 2024, relating to the sale of shares of our common stock, par value $0.10 per share, offered by this pros |
|
| April 10, 2024 |
IMMUCELL CORPORATION Common Stock Subscription Rights Filed Pursuant to Rule 424(b)(2) File No. 333-278438 Prospectus IMMUCELL CORPORATION $20,000,000 Common Stock Warrants Subscription Rights From time to time, we may offer up to $20,000,000.00 of our common stock, warrants and subscription rights, in one or more transactions. We will provide specific terms of these securities and offerings in one or more supplements to this prospectus. We may also |
|
| April 9, 2024 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 For Immediate Release PORTLAND, Maine – April 9, 2024 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, tod |
|
| April 9, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File |
|
| April 9, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 9, 2024 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT April 9, 2024 Craig-Hallum Capital Group LLC 222 South 9th Street, Suite 350 Minneapolis, MN 55402 Ladies and Gentlemen: ImmuCell Corporation, a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Craig-Hallum Capital Group LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, |
|
| April 9, 2024 |
Exhibit 10.1 CONSENT AND FIRST AMENDMENT TO ECONOMIC RECOVERY LOAN PROGRAM LOAN AGREEMENT This Consent and First Amendment to Economic Recovery Loan Program Loan Agreement (this “Amendment”) is made and dated as of April 8, 2024, by and between IMMUCELL CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Borrower”), the FINANCE AUTHORITY OF MAINE, a body |
|
| April 5, 2024 |
April 5, 2024 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 1, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) ImmuCell Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to Be Paid Equity Common Stock 457(o) Other Warrants 457(o) Other Rights 457(o) Unallocated (Universal) Shelf - 457(o) $ 20,000,000 N/A (2) $ 20,000,000 . |
|
| April 1, 2024 |
ImmuCell Corporation Clawback Policy. Exhibit 97.1 IMMUCELL CORPORATION CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of ImmuCell Corporation (the “Company”) has adopted this policy (the “Policy”) which provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under the federal securities laws. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of incorporation) (I.R.S. Employer Identification N |
|
| April 1, 2024 |
Exhibit 10.8 ImmuCell Corporation FIFTH AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This Fifth Amended and Restated Incentive Compensation Agreement, dated as of March 27, 2024, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Elizabeth L. Williams (the “Executive”), and replaces and supersedes in its entirety the Fourth Amended and Restated Incentive Co |
|
| April 1, 2024 |
Exhibit 10.11 ImmuCell Corporation FOURTH AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This Fourth Amended and Restated Incentive Compensation Agreement, dated as of March 27, 2024, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Bobbi Jo Brockmann (the “Executive”), and replaces and supersedes in its entirety the Third Amended and Restated Incentive Com |
|
| March 6, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 6, 2024 |
Exhibit 10.1 AMENDING AGREEMENT THIS AMENDING AGREEMENT is dated March 4, 2024 PARTIES: 1. NORBROOK LABORATORIES LIMITED, a company incorporated and registered in Northern Ireland with company number NI007665 and whose registered office address is at Station Works, Camlough Road, Newry, Co Down, BT35 6JP, Northern Ireland (“NORBROOK”); and 2. IMMUCELL CORPORATION a corporation duly organised and e |
|
| February 27, 2024 |
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 Exhibit 99.1 ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 For Immediate Release PORTLAND, Maine – February 27, 2024 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dai |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 22, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 27, 2024 |
Exhibit 10.1 ALLONGE TO AND AMENDMENT OF LINE OF CREDIT LOAN NO. 8160005222 AGREEMENT made this 22nd day of February 2024, between Immucell Corporation a Maine corporation (hereinafter called “Borrower”) and GORHAM SAVINGS BANK, a Maine banking corporation with principal place of business at 10 Wentworth Drive, Gorham, Maine 04038 (the “Bank”). Reference is hereby made to a certain Line of Credit |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 8, 2024 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023 Exhibit 99.1 ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023 For Immediate Release PORTLAND, Maine – January 8, 2024 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today anno |
|
| November 16, 2023 |
EXHIBIT 10.1 THIRD AMENDMENT OF LEASE This is a Third Amendment of Lease (this “Amendment”) is dated as of this 14th day of November, 2023, by and between TVP, LLC, with a mailing address of P.O. Box 66749, Falmouth, Maine 04105 (hereinafter the “Landlord”), and ImmuCell Corporation with a mailing address of 56 Evergreen Drive, Portland, Maine 04103 (hereinafter the “Tenant”). WHEREAS, the parties |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 13, 2023 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023 For Immediate Release PORTLAND, Maine – November 13, 2023 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of da |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Ident |
|
| November 13, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 5, 2023 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023 For Immediate Release PORTLAND, Maine – October 5, 2023 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, t |
|
| October 5, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identifica |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 10, 2023 |
Exhibit 4.1 ImmuCell Corporation AMENDMENT TO RIGHTS AGREEMENT THIS AMENDMENT is entered into as of August 9, 2023, between IMMUCELL CORPORATION, a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC., a New York corporation, as Rights Agent (the “Rights Agent”). WHEREAS, the Company and the Rights Agent are parties to (i) a Rights Agreement dated as of September 5, 1995, providi |
|
| August 10, 2023 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023 For Immediate Release PORTLAND, Maine – August 10, 2023 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and |
|
| July 21, 2023 |
Exhibit 10.4 ECONOMIC RECOVERY LOAN PROGRAM LOAN AGREEMENT This Loan Agreement is made and dated as of July 17, 2023, by and between IMMUCELL CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Borrower”), the FINANCE AUTHORITY OF MAINE, a body corporate and politic and a public instrumentality of the State of Maine (the “Authority”). WHEREAS, the Financ |
|
| July 21, 2023 |
Exhibit 10.3 ECONOMIC RECOVERY/SSBCI PROGRAM LOAN PROMISSORY NOTE $1,000,000.00 IMMUCELL CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Borrower”), for value received, hereby promises to pay to the Finance Authority of Maine, (the “Authority”), or order, the principal sum of ONE MILLION DOLLARS ($1,000,000.00) together with interest on the unpaid pr |
|
| July 21, 2023 |
Exhibit 10.2 LOAN AGREEMENT THIS LOAN AGREEMENT (“Agreement”) effective as of the 17 day of July, 2023, by and between IMMUCELL CORPORATION, a Delaware Corporation with a mailing address of 56 Evergreen Drive, Portland, Maine 04103 (hereinafter “Borrower”), and GORHAM SAVINGS BANK, a Maine banking company, with a mailing address of 10 Wentworth Drive, Gorham, Maine 04038, and its successors and as |
|
| July 21, 2023 |
Exhibit 10.1 TERM NOTE $2,000,000 July 17, 2023 FOR VALUE RECEIVED, IMMUCELL CORPORATION, a Delaware corporation with a place of business at 56 Evergreen Drive, Portland, Maine 04103 (the “Borrower”), promises to pay to the order of GORHAM SAVINGS BANK (“Lender”), the principal sum of Two Million and 00/100 Dollars ($2,000,000) or so much thereof as may be advanced and outstanding from time to tim |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 17, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 13, 2023 |
As filed with the Securities and Exchange Commission on July 13, 2023 As filed with the Securities and Exchange Commission on July 13, 2023 Registration No. |
|
| July 13, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) ImmuCell Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par va |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 11, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 11, 2023 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023 For Immediate Release PORTLAND, Maine – July 11, 2023 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, tod |
|
| June 29, 2023 |
ImmuCell Announces Change in Timing of Anticipated FDA Submission Exhibit 99.1 ImmuCell Announces Change in Timing of Anticipated FDA Submission PORTLAND, Maine, June 28, 2023 (GLOBE NEWSWIRE) - ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a ch |
|
| June 29, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 21, 2023 |
ImmuCell Appoints Bryan K. Gathagan to Board of Directors Exhibit 99.1 ImmuCell ImmuCell Appoints Bryan K. Gathagan to Board of Directors For Immediate Release PORTLAND, Maine – June 21, 2023 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announc |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identific |
|
| May 11, 2023 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023 For Immediate Release PORTLAND, Maine – May 11, 2023 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and b |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 28, 2023 |
DEF 14A 1 def14a0423immucell.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ImmuCell Corporation (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Filed by the Regist |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ImmuCell Corporation (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Filed by the Registrant ☒ Filed by a party other than the Registrant |
|
| April 5, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 5, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 5, 2023 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023 For Immediate Release PORTLAND, Maine – April 5, 2023 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, tod |
|
| March 29, 2023 |
Exhibit 10.7 AMENDMENT TO THE 2017 STOCK OPTION AND INCENTIVE PLAN The 2017 Stock Option and Incentive Plan (the “Plan”) of ImmuCell Corporation is amended as follows, effective as of June 15, 2022. 1. The second sentence of Section 5 of Part 1 of the Plan is replaced in its entirety by the following: The aggregate number of Shares which may be issued pursuant to this Plan shall be six hundred fif |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of incorporation) (I.R.S. Employer Identification N |
|
| March 29, 2023 |
Exhibit 10.23 ALLONGE TO AND AMENDMENT OF LINE OF CREDIT LOAN NO. 8160005222 AGREEMENT made this 23rd day of March 2022, between Immucell Corporation a Maine corporation (hereinafter called “Borrower”) and GORHAM SAVINGS BANK, a Maine banking corporation with principal place of business at 10 Wentworth Drive, Gorham, Maine 04038 (the “Bank”). Reference is hereby made to a certain Line of Credit (t |
|
| March 29, 2023 |
Exhibit 10.15 THIRD AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This Third Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2023, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Bobbi Jo Brockmann (the “Executive”), and replaces and supersedes in its entirety the Second Amended and Restated Incentive Compensation Agreement, d |
|
| March 29, 2023 |
Exhibit 10.13 AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT, dated as of March 28, 2023, is by and between IMMUCELL CORPORATION, a Delaware corporation (the “Company”) and MICHAEL F. BRIGHAM (the “Executive”), and replaces and supersedes in its entirety the Incentive Compensation Agreement, dated as of March 28, 2022, between the C |
|
| March 29, 2023 |
Exhibit 10.10 FOURTH AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This Fourth Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2023, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Elizabeth L. Williams (the “Executive”), and replaces and supersedes in its entirety the Third Amended and Restated Incentive Compensation Agreemen |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 21, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 21, 2023 |
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022 PORTLAND, Maine – February 21, 2023 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2023 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 9, 2023 |
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022 EX-99.1 2 ea171435ex99-1immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED JANUARY 9, 2023 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022 For Immediate Release PORTLAND, Maine – January 9, 2023 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and |
|
| November 21, 2022 |
Exhibit 4.1 ImmuCell Corporation AMENDMENT TO RIGHTS AGREEMENT THIS AMENDMENT is entered into as of August 10, 2022, between IMMUCELL CORPORATION, a Delaware corporation (the ?Company?), and American Stock Transfer & Trust Co., a New York corporation, as Rights Agent (the ?Rights Agent?). WHEREAS, the Company and the Rights Agent are parties to (i) a Rights Agreement dated as of September 5, 1995, |
|
| November 21, 2022 |
EXHIBIT 10 ImmuCell Corporation THIRD AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This Third Amended and Restated Incentive Compensation Agreement, dated as of November 11, 2022, is by and between ImmuCell Corporation, a Delaware corporation (the ?Company?) and Elizabeth L. |
|
| November 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Ident |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. E |
|
| November 21, 2022 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022 For Immediate Release PORTLAND, Maine ? November 21, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da |
|
| November 10, 2022 |
Exhibit 99.1 ImmuCell ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022 For Immediate Release Conference Call Scheduled for Tuesday, November 22, 2022 at 9:00 AM ET PORTLAND, Maine ? November 10, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-pro |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Estimated average burden hours per response ... 2.50 001-12934 SEC FILE NUMBER 452525 30 6 CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: September 30, 2022 o Transition |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 5, 2022 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022 For Immediate Release PORTLAND, Maine ? October 5, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and |
|
| October 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 15, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 17, 2022 |
EXHIBIT 99.1 SECOND AMENDMENT OF LEASE This is a Second Amendment of Lease (this ?Amendment?) is dated as of this 15th day of August, 2022, by and between TVP, LLC, with a mailing address of P.O. Box 66749, Falmouth, Maine 04105 (hereinafter the ?Landlord?), and ImmuCell Corporation with a mailing address of 56 Evergreen Drive, Portland, Maine 04103 (hereinafter the ?Tenant?). WHEREAS, the parties |
|
| August 11, 2022 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022 For Immediate Release PORTLAND, Maine ? August 11, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identifica |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 11, 2022 |
Amendment to Rights Agreement dated as of August 10, 2022. Exhibit 4.1 ImmuCell Corporation AMENDMENT TO RIGHTS AGREEMENT THIS AMENDMENT is entered into as of August 10, 2022, between IMMUCELL CORPORATION, a Delaware corporation (the ?Company?), and American Stock Transfer & Trust Co., a New York corporation, as Rights Agent (the ?Rights Agent?). WHEREAS, the Company and the Rights Agent are parties to (i) a Rights Agreement dated as of September 5, 1995, |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 27, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 28, 2022 |
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain® Exhibit 99.1 ImmuCell ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain? For Immediate Release PORTLAND, Maine ? July 27, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy an |
|
| July 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 7, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 7, 2022 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022 For Immediate Release PORTLAND, Maine ? July 7, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and be |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 12, 2022 |
Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022 Q1 2022 Product Sales Increased 46% over Q1 2021 For Immediate Release PORTLAND, Maine ? May 12, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that i |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identific |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 11, 2022 |
ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022 Exhibit 99.1 ImmuCell ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022 For Immediate Release PORTLAND, Maine ? April 11, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dair |
|
| April 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 11, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 30, 2022 |
Exhibit 10.8 SECOND AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This Second Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2022, is by and between ImmuCell Corporation, a Delaware corporation (the ?Company?) and Elizabeth L. Williams (the ?Executive?), and replaces and supersedes in its entirety the Amended and Restated Incentive Compensation Agreement, date |
|
| March 30, 2022 |
Exhibit 10.10 INCENTIVE COMPENSATION AGREEMENT This INCENTIVE COMPENSATION AGREEMENT, dated as of March 28, 2022, is by and between IMMUCELL CORPORATION, a Delaware corporation (the ?Company?) and MICHAEL F. BRIGHAM (the ?Executive?). WHEREAS, the Executive serves as the Company?s President, Chief Executive Officer and Treasurer; and WHEREAS, the Company wishes to provide the Executive with certai |
|
| March 30, 2022 |
Exhibit 10.11 SECOND AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This Second Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2022, is by and between ImmuCell Corporation, a Delaware corporation (the ?Company?) and Bobbi Jo Brockmann (the ?Executive?), and replaces and supersedes in its entirety the Amended and Restated Incentive Compensation Agreement, dated |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of incorporation) (I.R.S. Employer Identification N |
|
| March 30, 2022 |
Exhibit 10.9 AMENDED AND RESTATED SEPARATION AND DEFERRED COMPENSATION AGREEMENT This Amended and Restated Separation and Deferred Compensation Agreement, dated as of March 28, 2022, is by and between IMMUCELL CORPORATION, a Delaware corporation (the ?Company?) and MICHAEL F. BRIGHAM (the Executive?), and replaces and supersedes in its entirety the Severance Agreement, dated as of March 25, 2020, |
|
| March 24, 2022 |
ALLONGE TO AND AMENDMENT OF TERM NOTE Loan No. 8160005131 Exhibit 99.1 ALLONGE TO AND AMENDMENT OF TERM NOTE Loan No. 8160005131 This Allonge to and Amendment of Term Note (this ?Allonge?) refers to the loan evidenced by a Promissory Note (#8160005131) dated March 11, 2020 in the original amount of Five Million One Hundred Thousand and 00/100 Dollars ($5,100,000.00) (the ?Note?) executed by ImmuCell Corporation, a Delaware corporation (?Borrower?) in fav |
|
| March 24, 2022 |
Exhibit 99.2 MORTGAGE MODIFICATION AGREEMENT This Mortgage Modification Agreement will be recorded and made a part of a certain Mortgage Deed (the ?Mortgage?) dated March 11, 2020, and recorded in the Cumberland County Registry of Deeds in Book 36500, Page 77, and executed by Michael F. Brigham in his capacity as President and CEO of ImmuCell Corporation (?Grantor?) in favor of Gorham Savings Bank |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 22, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 22, 2022 |
Exhibit 99.1 ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021 Annual Product Sales for 2021 Increased 25% over 2020 For Immediate Release PORTLAND, Maine ? February 22, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically proven and practical pr |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 11, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 11, 2022 |
INDEPENDENT CONTRACTOR AGREEMENT Exhibit 99.1 INDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement (?Agreement?) is made and effective as of February 11, 2022 between Joseph Crabb (?Consultant?) and ImmuCell Corporation, a Delaware corporation (?Company?). Now, therefore, Consultant and Company agree as follows: 1. Resignation; Engagement. Consultant hereby resigns, effective 11:59 P.M. on February 11, 2022, fro |
|
| January 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2022 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 5, 2022 |
ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021 Exhibit 99.1 ImmuCell ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021 For Immediate Release PORTLAND, Maine ? January 5, 2022 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and producti |
|
| November 15, 2021 |
Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2021 Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000) For Immediate Release PORTLAND, Maine ? November 15, 2021 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-p |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Ident |
|
| November 15, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 6, 2021 |
ImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021 EX-99.1 2 ea148441ex99-1immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED OCTOBER 6, 2021 Exhibit 99.1 ImmuCell ImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021 For Immediate Release PORTLAND, Maine – October 6, 2021 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and mar |
|
| October 6, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 6, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 24, 2021 |
ImmuCell Required to Prepare Second Submission of Final Major Technical Section for Re-Tain® EX-99.1 2 ea146379ex99-1immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED AUGUST 24, 2021 Exhibit 99.1 ImmuCell ImmuCell Required to Prepare Second Submission of Final Major Technical Section for Re-Tain® For Immediate Release PORTLAND, Maine – August 24, 2021 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and |
|
| August 24, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identifica |
|
| August 12, 2021 |
EX-99.1 2 ea145625ex99-1immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED AUGUST 12, 2021 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2021 Bottom Line: Q2 2021 Net Income of $141,000 versus Q2 2020 Net Loss of ($766,000) For Immediate Release PORTLAND, Maine – August 12, 2021 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 7, 2021 |
ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021 EX-99.1 CHARTER 2 ea143854ex99-1immucell.htm EXHIBIT 99.1 Exhibit 99.1 ImmuCell ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021 For Immediate Release PORTLAND, Maine – July 7, 2021 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical |
|
| July 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 7, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 6, 2021 |
EXHIBIT 99.1 NOTE PURCHASE AGREEMENT This Note Purchase Agreement, (?Agreement?), is made as of June 30, 2021, by and between the Maine Technology Institute, a non-profit corporation organized under the laws of the State of Maine (?Holder?), and ImmuCell Corporation, a Corporation organized under the laws of the State of Delaware, Federal tax identification number 01-0382980 (?Company?) (collectiv |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 30, 2021 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 6, 2021 |
EX-99.2 3 ea143716ex99-2immucell.htm SUBORDINATED PROMISSORY NOTE FOR $400,000 EXECUTED BY IMMUCELL CORPORATION IN FAVOR OF THE MAINE TECHNOLOGY INSTITUTE DATED JUNE 30, 2021 EXHIBIT 99.2 SUBORDINATED PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. IT MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 16, 2021 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identific |
|
| May 13, 2021 |
ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2021 EX-99.1 2 ea140805ex99-1immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED MAY 13, 2021 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2021 For Immediate Release PORTLAND, Maine – May 13, 2021 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant S Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) S Defini |
|
| April 16, 2021 |
515,156 Shares of Common Stock ImmuCell Corporation Filed Pursuant to Rule 424(b)(5) Registration No.: 333-228479 PROSPECTUS SUPPLEMENT (To Prospectus dated November 29, 2018) 515,156 Shares of Common Stock ImmuCell Corporation We are offering 515,156 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on The Nasdaq Capital Market under the symbol “ICCC”. On April 13, 2021, t |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ImmuCell Corporation (Name of Issuer) Common Stock, $.10 par value (Title of Class of Securities) 452525306 Cusip Number Norman H. Pessin Sandra F. Pessin Brian L. Pessin 400 E 51st PH31 New York, NY 10022 212-808-4333 (Name, Address and Telephone Numbe |
|
| April 15, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 14, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 15, 2021 |
EX-10.1 3 ea139552ex10-1immucellcorp.htm SECURITIES PURCHASE AGREEMENT, DATED APRIL 14, 2021, BY AND AMONG IMMUCELL CORPORATION AND CERTAIN PURCHASERS Exhibit 10.1 THE COMPANY HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE COMMISSION FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER |
|
| April 15, 2021 |
ImmuCell Closes $4,250,000 Equity Financing EX-99.1 4 ea139552ex99-1immucellcorp.htm PRESS RELEASE OF THE COMPANY DATED APRIL 14, 2021 Exhibit 99.1 ImmuCell ImmuCell Closes $4,250,000 Equity Financing FOR IMMEDIATE RELEASE PORTLAND, Maine – April 14, 2021 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products th |
|
| April 7, 2021 |
ImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021 For Immediate Release PORTLAND, Maine ? April 7, 2021 ? ImmuCell Corporation (Nasdaq: ICCC) (?ImmuCell? or the ?Company?), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and be |
|
| April 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 7, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 30, 2021 |
Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of registered securities of ImmuCell Corporation (?us,? ?our,? ?we? or the ?Company?) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our certificate of incorporati |
|
| March 30, 2021 |
Exhibit 10.12 AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT BETWEEN THE COMPANY AND BOBBI JO BROCKMANN DATED AS OF MARCH 29, 2021 This Amended and Restated Incentive Compensation Agreement, dated as of March 29, 2021, is by and between ImmuCell Corporation, a Delaware corporation (the ?Company?) and Bobbi Jo Brockmann (the ?Executive?), and replaces and supersedes in its entirety the Amend |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 001-12934 (Commission file number) ImmuCell Corporation (Exact name of Registrant as specified in its charter) Delaware 01-0382980 (State of incorporation) (I.R.S. Employer Identification N |
|
| February 23, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 22, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 23, 2021 |
2 Condensed Statements of Operations (Unaudited) EX-99.1 2 ea136311ex99-1immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED FEBRUARY 22, 2021. Exhibit 99.1 ImmuCell ImmuCell Makes Important Regulatory Submission and Announces Unaudited Financial Results for the Year Ended December 31, 2020 For Immediate Release PORTLAND, Maine – February 22, 2021 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health c |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* IMMUCELL CORP /DE/ (Name of Issuer) Common Stock (Title of Class of Securities) 452525306 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* IMMUCELL CORP /DE/ (Name of Issuer) Common Stock (Title of Class of Securities) 452525306 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* IMMUCELL CORP /DE/ (Name of Issuer) Common Stock (Title of Class of Securities) 452525306 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| January 7, 2021 |
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2020 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2020 For Immediate Release PORTLAND, Maine – January 7, 2021 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of |
|
| January 7, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 7, 2021 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 17, 2020 |
ImmuCell Announces Restructuring of its Bank Debt Exhibit 99.1 ImmuCell ImmuCell Announces Restructuring of its Bank Debt For Immediate Release PORTLAND, Maine – December 15, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a |
|
| December 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2020 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 17, 2020 |
EX-10.2 3 ea131766ex10-2immucell.htm LOAN AGREEMENT FOR $1,500,000 EXECUTED BY IMMUCELL CORPORATION IN FAVOR OF GORHAM SAVINGS BANK DATED DECEMBER 15, 2020 Exhibit 10.2 LOAN AGREEMENT THIS LOAN AGREEMENT (“Agreement”) effective as of the 15th day of December, 2020, by and between IMMUCELL CORPORATION, a Delaware corporation with a place of business at 56 Evergreen Drive, Portland, Maine (referred |
|
| December 17, 2020 |
EX-10.1 2 ea131766ex10-1immucell.htm TERM NOTE FOR $1,500,000 EXECUTED BY IMMUCELL CORPORATION IN FAVOR OF GORHAM SAVINGS BANK DATED DECEMBER 15, 2020. Exhibit 10.1 TERM NOTE $1,500,000 December 15, 2020 FOR VALUE RECEIVED, IMMUCELL CORPORATION, a Delaware corporation with a place of business at 56 Evergreen Drive, Portland, Maine 04103 (the “Borrower”), promises to pay to the order of GORHAM SAVI |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 12, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 12, 2020 |
ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2020 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2020 For Immediate Release PORTLAND, Maine – November 12, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Ident |
|
| October 6, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 6, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 6, 2020 |
ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020 EX-99.1 2 ea127871ex99-1immucell.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED OCTOBER 6, 2020 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020 For Immediate Release PORTLAND, Maine – October 6, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures |
|
| August 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 12, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 12, 2020 |
ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2020 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2020 For Immediate Release PORTLAND, Maine – August 12, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of da |
|
| August 12, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identifica |
|
| July 7, 2020 |
ImmuCell Announces Preliminary, Unaudited Sales Results for the Second Quarter Ended June 30, 2020 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Sales Results for the Second Quarter Ended June 30, 2020 For Immediate Release PORTLAND, Maine – July 7, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity |
|
| July 7, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 7, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 16, 2020 |
APPENDIX B SUBORDINATED PROMISSORY NOTE Exhibit 99.3 APPENDIX B SUBORDINATED PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. IT MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. ImmuCell Corporation SUBORDINATED PROMISSORY |
|
| June 16, 2020 |
EX-99.2 3 ea123091ex99-2immucell.htm NOTE PURCHASE AGREEMENT EXECUTED BY IMMUCELL CORPORATION IN FAVOR OF THE MAINE TECHNOLOGY INSTITUTE DATED JUNE 12, 2020 EXHIBIT 99.2 Amount: $500,000.00 Match: $2,566,697.00 Award ID: 20190347 NOTE PURCHASE AGREEMENT This Note Purchase Agreement, (“Agreement”), is made as of 6/12/2020, by and between the Maine Technology Institute, a non-profit corporation orga |
|
| June 16, 2020 |
ImmuCell Receives $500,000 Loan from the Maine Technology Institute EX-99.1 2 ea123091ex99-1immucell.htm PRESS RELEASE OF THE COMPANY DATED JUNE 16, 2020 Exhibit 99.1 ImmuCell Receives $500,000 Loan from the Maine Technology Institute For Immediate Release PORTLAND, Maine – June 16, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical pr |
|
| June 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 12, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 11, 2020 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF IMMUCELL CORPORATION IMMUCELL CORPORATION, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: FIRST: That resolutions of the Board of Directors of ImmuCell Corporation were duly adopted setting forth a proposed amendment to the Certificate of I |
|
| June 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 10, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction (Commission File (IRS Employer of incorp |
|
| May 15, 2020 |
Exhibit 99.1 ImmuCell Corporation to Present at Lytham Partners Virtual Investor Conference On Tuesday, May 20th at 11:00 am ET Portland, Maine - May 14, 2020 - ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced it |
|
| May 15, 2020 |
Other Events, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 14, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction (Commission File (IRS Employer of incorpo |
|
| May 14, 2020 |
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders Exhibit 99.1 ImmuCell ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders For Immediate Release PORTLAND, Maine – May 14, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (the “Company” or “ImmuCell”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today annou |
|
| May 14, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 14, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE (State or other jurisdiction of incorporation) 001-12934 (Commission File Number) 01-038298 |
|
| May 13, 2020 |
ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2020 Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2020 For Immediate Release PORTLAND, Maine – May 13, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy |
|
| May 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 13, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| May 13, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identific |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant S Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) S Defini |
|
| April 14, 2020 |
ICCC / ImmuCell Corp. PRE 14A - - PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☐ Defini |
|
| April 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 13, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| April 14, 2020 |
ImmuCell Receives $938,000 in Support under the Paycheck Protection Program EX-99.1 2 ea120649ex99-1immucellcorp.htm PRESS RELEASE OF THE COMPANY DATED APRIL 14, 2020 Exhibit 99.1 ImmuCell ImmuCell Receives $938,000 in Support under the Paycheck Protection Program For Immediate Release PORTLAND, Maine – April 14, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically- |
|
| April 14, 2020 |
EX-99.2 3 ea120649ex99-2immucellcorp.htm PROMISSORY NOTE FOR $937,700 EXECUTED BY IMMUCELL CORPORATION IN FAVOR OF GORHAM SAVINGS BANK DATED APRIL 13, 2020 Exhibit 99.2 COMMERCIAL PROMISSORY NOTE Gorham Savings Bank 10 Wentworth Drive Gorham, Maine 04038 (207)839-4796 LOAN NUMBER NOTE DATE PRINCIPAL AMOUNT MATURITY DATE 8150055138 April 10, 2020 $ 937,700.00 April 10, 2022 LOAN PURPOSE: Paycheck P |
|
| April 2, 2020 |
ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended March 31, 2020 EX-99.1 2 ea120395ex99-1immucellcorp.htm PRESS RELEASE OF IMMUCELL CORPORATION DATED APRIL 2, 2020 Exhibit 99.1 ImmuCell ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Quarter Ended March 31, 2020 For Immediate Release PORTLAND, Maine – April 2, 2020 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufact |
|
| April 2, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 2, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 27, 2020 |
EXHIBIT 10.9 IMMUCELL CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT ImmuCell Corporation, a Delaware corporation (hereinafter the “Company”), hereby grants to (the “Optionee”), pursuant to the Company’s 2017 Stock Option and Incentive Plan (hereinafter the “2017 Plan”), a copy of which is attached hereto as Exhibit A, an Incentive Stock Option (the “Option”) to |
|
| March 27, 2020 |
EXHIBIT 10.21 AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT This Amended and Restated Incentive Compensation Agreement, dated as of March 25, 2020, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Bobbi Jo Brockmann (the “Executive”), and replaces and supersedes in its entirety the Incentive Compensation Agreement, dated as of April 11, 2019, between the C |
|
| March 27, 2020 |
ICCC / ImmuCell Corp. S-8 - - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on March 27, 2020 Registration No. |
|
| March 27, 2020 |
ICCC / ImmuCell Corp. 10-K - Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 001-12934 (Commission file number) ImmuCell Corporation (Exact name of Registrant as specified in its charter) Delaware 01-0382980 (State of incorporation) (I.R.S. Employer Identification N |
|
| March 27, 2020 |
Severance Agreement between the Company and Michael F. Brigham dated as of March 25, 2020. EXHIBIT 10.20 SEVERANCE AGREEMENT This Severance Agreement, dated as of March 25, 2020, is by and between IMMUCELL CORPORATION, a Delaware corporation (the “Company”) and MICHAEL F. BRIGHAM (the Executive”). WHEREAS, the Executive serves as the Company’s President, Chief Executive Officer and Treasurer; and WHEREAS, the Company wishes to provide the Executive with certain benefits and assurances i |
|
| March 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 11, 2020 (Date of earliest event reported) ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| March 12, 2020 |
Exhibit 99.2 TERM NOTE $5,100,000 March 11, 2020 FOR VALUE RECEIVED, IMMUCELL CORPORATION, a Delaware corporation (hereinafter the “Borrower”), promises to pay to the order of GORHAM SAVINGS BANK (“Lender”) the principal sum of FIVE MILLION ONE HUNDRED THOUSAND AND 00/100 ($5,100,000) (or so much thereof as may be advanced and outstanding from time to time) together with interest thereon at a rate |
|
| March 12, 2020 |
LINE OF CREDIT AGREEMENT (Working Capital Line) Exhibit 99.6 LINE OF CREDIT AGREEMENT (Working Capital Line) THIS LINE OF CREDIT AGREEMENT is by and between IMMUCELL CORPORATION, a Delaware corporation with principal place of business at 56 Evergreen Drive, Portland, County of Cumberland and State of Maine (“Borrower”) and GORHAM SAVINGS BANK, a Maine banking corporation with a principal place of business at 10 Wentworth Drive, Gorham, Maine 04 |
